Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

JPMORGAN HEALTHCARE LEADERS ETF

59.56
+0.08390.14%
Post-market: 59.47-0.0839-0.14%16:10 EDT
Volume:46
Turnover:3K
Market Cap:8.93M
PE:- -
High:59.56
Open:59.47
Low:59.56
Close:59.47
52wk High:64.69
52wk Low:53.59
Shares:150.00K
Float Shares:150.00K
Volume Ratio:0.55
T/O Rate:0.03%
Dividend:0.51
Dividend Rate:0.86%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

OverviewCompanyNewsFilings

Perrigo Co. PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 26

Eli Lilly Gets Expanded Label Approval from FDA for Alopecia Drug

Dow Jones
·
Sep 26

FDA Approves Lilly's Olumiant (Baricitinib) for Pediatric Patients 12 Years of Age and Older with Severe Alopecia Areata

THOMSON REUTERS
·
Sep 26

Merck, Daiichi Sankyo Withdraw US Application for Lung Cancer Drug

Reuters
·
Sep 26

Merck, Daiichi Sankyo voluntarily withdraw BLA for ifinatamab deruxtecan

TIPRANKS
·
Sep 26

Merck & Co - Daiichi Sankyo and Merck Withdraw Bla for Ifinatamab Deruxtecan in Es-Sclc in U.S.

THOMSON REUTERS
·
Sep 26

Merck & Co - Withdrawal Based on FDA Discussions; Phase 2 Data Do not Satisfy Approval Requirements

THOMSON REUTERS
·
Sep 26

Merck & Co - Patient Enrollment Continues in Ideate-Lung02 Phase 3 Trial for Ifinatamab Deruxtecan

THOMSON REUTERS
·
Sep 26

Merck & Co - Two Additional Phase 3 Trials Underway for Ifinatamab Deruxtecan in Crpc and Escc

THOMSON REUTERS
·
Sep 26

UnitedHealth Announces R$ 0.115248942 Dividend Per Unit for 3Q 2026

Reuters
·
Sep 26

ADARx Pharmaceuticals Shares Soar in NASDAQ Debut After Upsized IPO

Reuters
·
Sep 26

Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case

MT Newswires Live
·
Sep 26

Innovation is Driving a New Bull Market in Biotech. 16 Ways to Play It, from Our Roundtable Experts.

Dow Jones
·
Sep 25

ADARx Pharmaceuticals indicated to open at $28, IPO priced at $17

TIPRANKS
·
Sep 25

Sector Update: Healthcare Stocks Edge Higher Premarket Friday

MT Newswires Live
·
Sep 25

Johnson & Johnson Says Tremfya Significantly Improves Axial Psoriatic Arthritis Symptoms in Phase 4 Study

MT Newswires Live
·
Sep 25

Novo Bets on Next Chapter While Eli Lilly Extends Its GLP-1 Dominance

Deep News
·
Sep 25

Johnson & Johnson says Tremfya met endpoints in Phase 4 STAR study

TIPRANKS
·
Sep 25

J&J - Star Study Shows Tremfya Safety Profile Consistent with Psa; no New Safety Signals

THOMSON REUTERS
·
Sep 25

J&J - Tremfya Meets Primary Endpoint for Basdai Score Improvement at Week 24

THOMSON REUTERS
·
Sep 25
More